1. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group
2. 2 TR Kreil . Prion Partitioning during Plasma Fractionation: A Consolidated View. Presented to the Joint meeting of the FDA's Transmissible Spongiform Encephalopathy Advisory Committee and Blood Products Advisory Committee, 17 January 2002. On http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3834t2_01.pdf. Accessed on 12 April 2004.
3. 3 Food and Drug Administration . Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. 2001 . Available at http://www.fda.gov/cber/gdlns/cjdvcjd.pdf. Accessed on 12 April 2004.
4. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B